Lucien Courtois
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucien Courtois has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Guillaume P. Andrieu
Institut Necker-Enfants Malades
21 shared publications - Nicolas Boissel
Hôpital Saint-Louis, AP-HP, Paris, France
21 shared publications - Elizabeth Macintyre
University Paris Cité and Assistance Publique-Hôpitaux de Paris, AP-HP Centre, Paris, France
20 shared publications - Antoine Pinton
Institut Necker Enfants Malades, INSERM U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Université Paris Cité, Paris, France
19 shared publications - Aurore Touzart
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
19 shared publications - Charlotte Smith
Université Paris Cité, Institut Necker Enfants-Malades INEM, Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, Paris, France
19 shared publications
Latest Publications
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2793-2808
Homeodomain-driven oncogenic diversion to a γδTCR phenotype in T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) results from the malignant transformation of thymocytes blocked in their differentiation. Surface expression of the γδ T-cell receptor (γδTCR) is surprisingly frequent in T-ALLs, questioning the susceptibility of the γδ-lineage to leukemogenesis. Among 1233 T-ALLs phenotyped in our center, 33% (n = 403) expressed a TCR, of which 47% (n = 191; 113 adults, 78 children) were positive for γδTCR (γδTCR+). Using a comprehensive analysis, we were able to delineate 2 distinct γδTCR+ T-ALL subtypes, with distinct physiological counterparts. The first (75% of cases) was characterized by ectopic expression of homeodomain-containing oncogenes (HD+), Vβ-Jβ rearrangements, and phenotypic (including surface pre-TCRα chain) and transcriptional profiles reminiscent of cortical thymocytes and was, therefore, termed cortical-like γδ T-ALLs. Transduction of murine T-cell progenitors and human CD34+ cells with HOXA9 or TLX3 (HD+ oncogenes) led to a differentiation bias toward γδTCR-expressing thymocytes. The second subtype (25%) exhibited phenotypic and transcriptional profiles reminiscent of γδ thymocytes, and was termed bona fide γδ T-ALLs. These findings were validated in the COGAALL0434 cohort. Although bona fide γδ T-ALLs were enriched for early T-cell progenitor (ETP)–like and KMT2A-rearranged cases, they mostly eluded the phenotypic definition of ETP-ALLs. Similar to the ETP-like subtype, bona fide γδ T-ALLs were associated with a poor initial response to chemotherapy but were sensitive to the BCL2 inhibitor venetoclax. Our results reveal developmental heterogeneity behind γδTCR expression in T-ALLs and suggest that overrepresentation of this subtype reflects αβ-lineage commitment repression by HD+ oncogenes. These trials were registered at www.clinicaltrials.gov as NCT00222027 (GRAALL2003), NCT00327678 (GRAALL2005), NCT03709719 (GRAALL2014), and NCT00408005 (Children's Oncology Group AALL0434 trial).
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2793-2808
Homeodomain-driven oncogenic diversion to a γδTCR phenotype in T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) results from the malignant transformation of thymocytes blocked in their differentiation. Surface expression of the γδ T-cell receptor (γδTCR) is surprisingly frequent in T-ALLs, questioning the susceptibility of the γδ-lineage to leukemogenesis. Among 1233 T-ALLs phenotyped in our center, 33% (n = 403) expressed a TCR, of which 47% (n = 191; 113 adults, 78 children) were positive for γδTCR (γδTCR+). Using a comprehensive analysis, we were able to delineate 2 distinct γδTCR+ T-ALL subtypes, with distinct physiological counterparts. The first (75% of cases) was characterized by ectopic expression of homeodomain-containing oncogenes (HD+), Vβ-Jβ rearrangements, and phenotypic (including surface pre-TCRα chain) and transcriptional profiles reminiscent of cortical thymocytes and was, therefore, termed cortical-like γδ T-ALLs. Transduction of murine T-cell progenitors and human CD34+ cells with HOXA9 or TLX3 (HD+ oncogenes) led to a differentiation bias toward γδTCR-expressing thymocytes. The second subtype (25%) exhibited phenotypic and transcriptional profiles reminiscent of γδ thymocytes, and was termed bona fide γδ T-ALLs. These findings were validated in the COGAALL0434 cohort. Although bona fide γδ T-ALLs were enriched for early T-cell progenitor (ETP)–like and KMT2A-rearranged cases, they mostly eluded the phenotypic definition of ETP-ALLs. Similar to the ETP-like subtype, bona fide γδ T-ALLs were associated with a poor initial response to chemotherapy but were sensitive to the BCL2 inhibitor venetoclax. Our results reveal developmental heterogeneity behind γδTCR expression in T-ALLs and suggest that overrepresentation of this subtype reflects αβ-lineage commitment repression by HD+ oncogenes. These trials were registered at www.clinicaltrials.gov as NCT00222027 (GRAALL2003), NCT00327678 (GRAALL2005), NCT03709719 (GRAALL2014), and NCT00408005 (Children's Oncology Group AALL0434 trial).
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation et ciblage thérapeutique des voies de signalisation médiées par le récepteur à l'IL-7 et le pré-TCR dans les leucémies aiguës lymphoblastiques T
La thymopoïèse est un processus hautement contrôlé par les voies de signalisation issues de récepteurs comme celui de l'interleukine 7 (IL-7R) ainsi que par les points de contrôle fixés par le pré-TCR et le TCR. Les leucémies aiguës lymphoblastiques T (LAL-T) résultent de la transformation des progéniteurs T (ou thymocytes) et de leur blocage à des stades de différenciation spécifiques. Le pronostic des LAL-T reste médiocre, notamment en situation chimio réfractaire ou de rechute (LAL-T R/R). Les bases génétiques des LAL-T sont bien caractérisées mais ne se sont pas traduites en cibles thérapeutiques efficaces. Il existe donc un besoin urgent de développer de nouvelles options thérapeutiques pour les LAL-T R/R. Dans ce travail, nous avons testé l'hypothèse selon laquelle des facteurs majeurs impliqués dans la thymopoïèse (signalisations issues de l'IL-7R et du pré-TCR) peuvent rester essentiels au maintien des LAL-T, et constituer ainsi des cibles thérapeutiques. Nous avons d'abord caractérisé l'expression de l'IL-7R sur une grande cohorte de LAL-T adultes (n=200) par cytométrie en flux (CMF). La combinaison de ces données d'expression aux données mutationnelles nous a permis de définir 3 catégories de LAL-T : 1/présence de mutations activatrices de la voie IL7R/JAK/STAT (IL-7R+/Mut), 2/expression de l'IL-7R en l'absence de ces mutations (IL-7R+/WT), 3/absence d'expression de l'IL-7R (IL-7R-/WT). Grâce à l'utilisation d'un grand nombre de xénogreffes dérivées de patients (PDX, n=46), nous montrons que l'efficacité thérapeutique des inhibiteurs de JAK (ruxolitinib/tofacitinib-JAKinibs) s'étend au-delà des seules LAL-T IL-7R+/Mut, pour englober les LAL-T IL-7R+/WT, positionnant ainsi l'expression de l'IL-7R comme meilleur biomarqueur de réponse à ces thérapies ciblées que la seule présence de mutations. Nous montrons également que l'efficacité des JAKinibs sur les LAL-T IL-7R+ peut être potentialisée par leur combinaison à l'inhibiteur de Bcl-2 venetoclax, et que cette combinaison peut être utilisée dans les LAL-T R/R comme stratégie de pont vers l'allogreffe. Pour identifier les LAL-T dépendantes de la signalisation issue du pre-TCR, nous avons évalué le niveau de phosphorylation, et donc d'activation, de la kinase LCK par CMF, sur plus de 40 PDX représentatives des différents sous-types de LAL-T. Nous montrons que LCK est souvent activée dans les LAL-T de phénotype pré-ab/cortical et que ces dernières expriment un pré-TCR de surface. De manière intéressante, ces LAL-T sont sensibles à l'inhibition de LCK exercée par le dasatinib, mais à des temps d'exposition relativement long. Dans ce contexte, et en nous appuyant sur les données d'expression de l'IL-7R, nous montrons que la co-inhibition des voies de signalisation issues du pre-TCR et de l'IL-7R est fortement synergique dans les LAL-T corticales IL-7R+, et que cette co-inhibition améliore significativement la survie, par rapport à l'inhibition isolée de chaque voie, dans une PDX de LAL-T corticale. Enfin, nous avons observé qu'une proportion significative de LAL-T exprimant un TCRgd présentaient étrangement un phénotype cortical, avec parfois même une expression du pre-TCR en surface. Une analyse intégrée (oncogénétique, immunogénétique, immunophénotypique et transcriptomique) d'une grande cohorte de LAL-T TCRgd (n=157) montre que celles-ci peuvent être divisées en 2 catégories distinctes : une caractérisée par la surexpression d'oncogènes à homéodomaine (HD+), un stade d'arrêt de maturation cortical et probablement dérivée de thymocytes ab, tandis que l'autre se caractérise par l'absence d'expression de ces oncogènes (HD-) et pourrait représenter la contrepartie leucémique des thymocytes gd. Collectivement, nos résultats montrent que des voies de signalisation supportant le développement physiologique peuvent constituer des cibles thérapeutiques intéressantes dans un contexte tumoral et apportent de nouveaux éléments sur l'oncogénèse des LAL-T corticales.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation et ciblage thérapeutique des voies de signalisation médiées par le récepteur à l'IL-7 et le pré-TCR dans les leucémies aiguës lymphoblastiques T
La thymopoïèse est un processus hautement contrôlé par les voies de signalisation issues de récepteurs comme celui de l'interleukine 7 (IL-7R) ainsi que par les points de contrôle fixés par le pré-TCR et le TCR. Les leucémies aiguës lymphoblastiques T (LAL-T) résultent de la transformation des progéniteurs T (ou thymocytes) et de leur blocage à des stades de différenciation spécifiques. Le pronostic des LAL-T reste médiocre, notamment en situation chimio réfractaire ou de rechute (LAL-T R/R). Les bases génétiques des LAL-T sont bien caractérisées mais ne se sont pas traduites en cibles thérapeutiques efficaces. Il existe donc un besoin urgent de développer de nouvelles options thérapeutiques pour les LAL-T R/R. Dans ce travail, nous avons testé l'hypothèse selon laquelle des facteurs majeurs impliqués dans la thymopoïèse (signalisations issues de l'IL-7R et du pré-TCR) peuvent rester essentiels au maintien des LAL-T, et constituer ainsi des cibles thérapeutiques. Nous avons d'abord caractérisé l'expression de l'IL-7R sur une grande cohorte de LAL-T adultes (n=200) par cytométrie en flux (CMF). La combinaison de ces données d'expression aux données mutationnelles nous a permis de définir 3 catégories de LAL-T : 1/présence de mutations activatrices de la voie IL7R/JAK/STAT (IL-7R+/Mut), 2/expression de l'IL-7R en l'absence de ces mutations (IL-7R+/WT), 3/absence d'expression de l'IL-7R (IL-7R-/WT). Grâce à l'utilisation d'un grand nombre de xénogreffes dérivées de patients (PDX, n=46), nous montrons que l'efficacité thérapeutique des inhibiteurs de JAK (ruxolitinib/tofacitinib-JAKinibs) s'étend au-delà des seules LAL-T IL-7R+/Mut, pour englober les LAL-T IL-7R+/WT, positionnant ainsi l'expression de l'IL-7R comme meilleur biomarqueur de réponse à ces thérapies ciblées que la seule présence de mutations. Nous montrons également que l'efficacité des JAKinibs sur les LAL-T IL-7R+ peut être potentialisée par leur combinaison à l'inhibiteur de Bcl-2 venetoclax, et que cette combinaison peut être utilisée dans les LAL-T R/R comme stratégie de pont vers l'allogreffe. Pour identifier les LAL-T dépendantes de la signalisation issue du pre-TCR, nous avons évalué le niveau de phosphorylation, et donc d'activation, de la kinase LCK par CMF, sur plus de 40 PDX représentatives des différents sous-types de LAL-T. Nous montrons que LCK est souvent activée dans les LAL-T de phénotype pré-ab/cortical et que ces dernières expriment un pré-TCR de surface. De manière intéressante, ces LAL-T sont sensibles à l'inhibition de LCK exercée par le dasatinib, mais à des temps d'exposition relativement long. Dans ce contexte, et en nous appuyant sur les données d'expression de l'IL-7R, nous montrons que la co-inhibition des voies de signalisation issues du pre-TCR et de l'IL-7R est fortement synergique dans les LAL-T corticales IL-7R+, et que cette co-inhibition améliore significativement la survie, par rapport à l'inhibition isolée de chaque voie, dans une PDX de LAL-T corticale. Enfin, nous avons observé qu'une proportion significative de LAL-T exprimant un TCRgd présentaient étrangement un phénotype cortical, avec parfois même une expression du pre-TCR en surface. Une analyse intégrée (oncogénétique, immunogénétique, immunophénotypique et transcriptomique) d'une grande cohorte de LAL-T TCRgd (n=157) montre que celles-ci peuvent être divisées en 2 catégories distinctes : une caractérisée par la surexpression d'oncogènes à homéodomaine (HD+), un stade d'arrêt de maturation cortical et probablement dérivée de thymocytes ab, tandis que l'autre se caractérise par l'absence d'expression de ces oncogènes (HD-) et pourrait représenter la contrepartie leucémique des thymocytes gd. Collectivement, nos résultats montrent que des voies de signalisation supportant le développement physiologique peuvent constituer des cibles thérapeutiques intéressantes dans un contexte tumoral et apportent de nouveaux éléments sur l'oncogénèse des LAL-T corticales.
- 12 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (24) , 2903-2913
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as dasatinib, often results in transient clinical responses, emphasizing the need for efficient combination strategies. Here, we assessed pre-TCR α chain (pTα) surface expression by flow cytometry in a unique series of 50 adult T-ALL patient-derived xenografts (PDXs). We show that cases displaying a cortical phenotype often express high levels of surface pTα (pre-TCR+ T-ALL) and that the latter associates with LCK activation. Furthermore, we show that ectopic interleukin-7 receptor (IL-7R) expression can rescue pre-TCR+ T-ALL from dasatinib cytotoxicity (5 PDXs). We tested whether coinhibition of pre-TCR and IL-7R signaling pathways could be synergetic in pre-TCR+ IL-7R+ T-ALL (11 PDXs). Combination of JAK inhibitors, ruxolitinib or tofacitinib, with dasatinib elicited strong and specific synergy in IL-7R+ pre-TCR+ T-ALL in vitro, including in the relapse setting (4 of 28 patient-derived primary samples). Using 3 adult-PDX models, we show that in vivo treatment with this combination significantly delayed leukemic progression and prolonged survival compared with either monotherapy. This preclinical study thus proposes the use of pTα as a biomarker of LCK-inhibitor sensitivity in T-ALL, and suggests that dual targeting of IL-7R and pre-TCR signaling pathways may be a relevant therapeutic strategy in a substantial proportion of adult T-ALL.
- 12 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (24) , 2903-2913
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as dasatinib, often results in transient clinical responses, emphasizing the need for efficient combination strategies. Here, we assessed pre-TCR α chain (pTα) surface expression by flow cytometry in a unique series of 50 adult T-ALL patient-derived xenografts (PDXs). We show that cases displaying a cortical phenotype often express high levels of surface pTα (pre-TCR+ T-ALL) and that the latter associates with LCK activation. Furthermore, we show that ectopic interleukin-7 receptor (IL-7R) expression can rescue pre-TCR+ T-ALL from dasatinib cytotoxicity (5 PDXs). We tested whether coinhibition of pre-TCR and IL-7R signaling pathways could be synergetic in pre-TCR+ IL-7R+ T-ALL (11 PDXs). Combination of JAK inhibitors, ruxolitinib or tofacitinib, with dasatinib elicited strong and specific synergy in IL-7R+ pre-TCR+ T-ALL in vitro, including in the relapse setting (4 of 28 patient-derived primary samples). Using 3 adult-PDX models, we show that in vivo treatment with this combination significantly delayed leukemic progression and prolonged survival compared with either monotherapy. This preclinical study thus proposes the use of pTα as a biomarker of LCK-inhibitor sensitivity in T-ALL, and suggests that dual targeting of IL-7R and pre-TCR signaling pathways may be a relevant therapeutic strategy in a substantial proportion of adult T-ALL.
- 29 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (9) , 988-1000
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
Given the poor outcome of refractory and relapsing T-cell acute lymphoblastic leukemia (T-ALL), identifying prognostic markers is still challenging. Using single nucleotide polymorphism (SNP) array analysis, we provide a comprehensive analysis of genomic imbalances in a cohort of 317 newly diagnosed patients with T-ALL including 135 children and 182 adults with respect to clinical and biological features and outcomes. SNP array results identified at least 1 somatic genomic imbalance in virtually all patients with T-ALL (∼96%). Del(9)(p21) (∼70%) and UPD(9)p21)/CDKN2A/B (∼28%) were the most frequent genomic imbalances. Unexpectedly del(13)(q14)/RB1/DLEU1 (∼14%) was the second most frequent copy number variant followed by del(6)(q15)/CASP8AP2 (∼11%), del(1)(p33)/SIL-TAL1 (∼11%), del(12)(p13)ETV6/CDKN1B (∼9%), del(18)(p11)/PTPN2 (∼9%), del(1)(p36)/RPL22 (∼9%), and del(17)(q11)/NF1/SUZ12 (∼8%). SNP array also revealed distinct profiles of genomic imbalances according to age, immunophenotype, and oncogenetic subgroups. In particular, adult patients with T-ALL demonstrated a significantly higher incidence of del(1)(p36)/RPL22, and del(13)(q14)/RB1/DLEU1, and lower incidence of del(9)(p21) and UPD(9p21)/CDKN2A/B. We determined a threshold of 15 genomic imbalances to stratify patients into high- and low-risk groups of relapse. Survival analysis also revealed the poor outcome, despite the low number of affected cases, conferred by the presence of chromothripsis (n = 6, ∼2%), del(16)(p13)/CREBBP (n = 15, ∼5%) as well as the newly-identified recurrent gain at 6q27 involving MLLT4 (n = 10, ∼3%). Genomic complexity, del(16)(p13)/CREBBP and gain at 6q27 involving MLLT4, maintained their significance in multivariate analysis for survival outcome. Our study thus demonstrated that whole genome analysis of imbalances provides new insights to refine risk stratification in T-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, and as #FRALLE 2000T trial.
- 29 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (9) , 988-1000
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
Given the poor outcome of refractory and relapsing T-cell acute lymphoblastic leukemia (T-ALL), identifying prognostic markers is still challenging. Using single nucleotide polymorphism (SNP) array analysis, we provide a comprehensive analysis of genomic imbalances in a cohort of 317 newly diagnosed patients with T-ALL including 135 children and 182 adults with respect to clinical and biological features and outcomes. SNP array results identified at least 1 somatic genomic imbalance in virtually all patients with T-ALL (∼96%). Del(9)(p21) (∼70%) and UPD(9)p21)/CDKN2A/B (∼28%) were the most frequent genomic imbalances. Unexpectedly del(13)(q14)/RB1/DLEU1 (∼14%) was the second most frequent copy number variant followed by del(6)(q15)/CASP8AP2 (∼11%), del(1)(p33)/SIL-TAL1 (∼11%), del(12)(p13)ETV6/CDKN1B (∼9%), del(18)(p11)/PTPN2 (∼9%), del(1)(p36)/RPL22 (∼9%), and del(17)(q11)/NF1/SUZ12 (∼8%). SNP array also revealed distinct profiles of genomic imbalances according to age, immunophenotype, and oncogenetic subgroups. In particular, adult patients with T-ALL demonstrated a significantly higher incidence of del(1)(p36)/RPL22, and del(13)(q14)/RB1/DLEU1, and lower incidence of del(9)(p21) and UPD(9p21)/CDKN2A/B. We determined a threshold of 15 genomic imbalances to stratify patients into high- and low-risk groups of relapse. Survival analysis also revealed the poor outcome, despite the low number of affected cases, conferred by the presence of chromothripsis (n = 6, ∼2%), del(16)(p13)/CREBBP (n = 15, ∼5%) as well as the newly-identified recurrent gain at 6q27 involving MLLT4 (n = 10, ∼3%). Genomic complexity, del(16)(p13)/CREBBP and gain at 6q27 involving MLLT4, maintained their significance in multivariate analysis for survival outcome. Our study thus demonstrated that whole genome analysis of imbalances provides new insights to refine risk stratification in T-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, and as #FRALLE 2000T trial.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the French trial Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 and retrospectively analyzed clinical outcomes between PHF6-altered (PHF6ALT) and wild-type patients. We also used EPIC and chromatin immunoprecipitation sequencing data of patient samples to analyze the epigenetic landscape of PHF6ALT T-ALLs. We consecutively evaluated 5-azacitidine efficacy, alone or combined with venetoclax, in PHF6ALT T-ALL.Results:We show that PHF6 alterations account for 47% of cases in our cohort and demonstrate that PHF6ALT T-ALL presented significantly better clinical outcomes. Integrative analysis of DNA methylation and histone marks shows that PHF6ALT are characterized by DNA hypermethylation and H3K27me3 loss at promoters physiologically bivalent in thymocytes. Using patient-derived xenografts, we show that PHF6ALT T-ALL respond to the 5-azacytidine alone. Finally, synergism with the BCL2-inhibitor venetoclax was demonstrated in refractory/relapsing (R/R) PHF6ALT T-ALL using fresh samples. Importantly, we report three cases of R/R PHF6ALT patients who were successfully treated with this combination.Conclusions:Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the French trial Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 and retrospectively analyzed clinical outcomes between PHF6-altered (PHF6ALT) and wild-type patients. We also used EPIC and chromatin immunoprecipitation sequencing data of patient samples to analyze the epigenetic landscape of PHF6ALT T-ALLs. We consecutively evaluated 5-azacitidine efficacy, alone or combined with venetoclax, in PHF6ALT T-ALL.Results:We show that PHF6 alterations account for 47% of cases in our cohort and demonstrate that PHF6ALT T-ALL presented significantly better clinical outcomes. Integrative analysis of DNA methylation and histone marks shows that PHF6ALT are characterized by DNA hypermethylation and H3K27me3 loss at promoters physiologically bivalent in thymocytes. Using patient-derived xenografts, we show that PHF6ALT T-ALL respond to the 5-azacytidine alone. Finally, synergism with the BCL2-inhibitor venetoclax was demonstrated in refractory/relapsing (R/R) PHF6ALT T-ALL using fresh samples. Importantly, we report three cases of R/R PHF6ALT patients who were successfully treated with this combination.Conclusions:Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients within the cluster 5 (Top). Table depicting the number of individuals according to timepoints.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients within the cluster 5 (Top). Table depicting the number of individuals according to timepoints.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.